Zim Laboratories Ltd. · NSE:ZIMLAB
Zim Laboratories — Q1 FY25 Earnings Presentation
15 slides from Zim Laboratories's earnings presentation, Aug 3, 2024
Slide 1: Exchange filing cover letter
Ref No.: ZLL/CS/BSE/NSE Date: 03.08.2024 BSE Limited, National Stock Exchange of India Limited Market Operations Dept. Listing Compliance Department P. J. Towers, Dalal Street, Exchange Plaza, Bandra-Kurla Complex, Mumbai- 400 001 Bandra (E), Mumbai – 400 051 Company Code- 541400 (Symbol - ZIMLAB) D
Slide 2: Q1 FY25 – Earnings Presentation
ZIM LABORATORIES LIMITED Q1 FY25 – EARNINGS PRESENTATION
Slide 3: Safe Harbour
SAFE HARBOUR The presentation has been prepared by ZIM Laboratories Limited (“ZIM” or the “Company”) solely for information purposes and does not constitute an offer to sell or recommendation or solicitation of an offer to subscribe for or purchase any securities and nothing contained herein shall f
Slide 4: Content
CONTENT 01 BUSINESS MODEL 02 Q1FY25 HIGHLIGHTS 03 BUSINESS MIX 04 R&D & INNOVATION 05 SHAREHOLDING 3
Slide 5: Integrated Business Model
INTEGRATED BUSINESS MODEL Business Distinct Offerings End-to-End Product Development Segments Across therapy segments and Dosage forms Offerings Therapy Segments Conceptualisation involves R&D Tablets Anti - Infective 01. Product Conceptualisation Export o FF and product research to examine feasibil
Slide 6: Q1FY25 Highlights
Q1FY25 HIGHLIGHTS Financial Highlights Business Highlights Total operating income increased ZIM was granted NIP Marketing 21.4% YoY; ₹818 Mn in Q1FY25 vs Authorisation (MA) in EU for ₹674 Mn in Q1FY24 Azithromycin Oral Suspension EBITDA increased to ₹90 Mn in ZIM filed 1 NIP & 1 OTF dossier Q1FY25 v
Slide 7: Financial Performance – Q1FY25
FINANCIAL PERFORMANCE – Q1FY25 Total Operating Income EBITDA & EBITDA margin Profit After Tax (PAT) & PAT margin 8.8% 11% 0.3% 1.1% 818 90 9 674 59 2 Q1FY24 Q1FY25 Q1FY24 Q1FY25 Q1FY24 Q1FY25 Total Operating Income (₹ Mn) EBITDA (₹ Mn) PAT (₹ Mn) o Total Operating Income grew 21.4% YoY, driven by in
Slide 8: Business Mix
BUSINESS MIX Pharma Revenue (₹ Mn) & Contribution to Total Nutra Revenue (₹ Mn) & Contribution to Total Operating Income (%) Operating Income (%) 33% 86% 83% 80% 74% 26% 67% 20% 17% 14% 978 255 266 740 708 201 540 552 134 118 Q1FY24 Q2 Q3 Q4 Q1FY25 Q1FY24 Q2 Q3 Q4 Q1FY25 Pharma Nutra o Q1FY25 : Phar
Slide 9: Revenue Mix
REVENUE MIX Q1FY24 Q1FY25 FY23 FY24 46, 7% 32, 4% 246, 6% 77, 9% 357, 9% 158, 4% 89, 13% 646, 18% 539, 80% 3,382, 2,870, 709, 87% 85% 78% Export India Deemed Export Numbers in ₹Mn o Q1FY25 : Export business grew 31.6% YoY reaching ₹709 Mn in Q1FY25 vs ₹539 Mn in Q1FY24 o India business contributed ₹
Slide 10: Revenue Contribution from NIP + OTF
REVENUE CONTRIBUTION FROM NIP + OTF NIP Revenue (₹ Mn) & Contribution to Total OTF Revenue (₹ Mn) and Contribution to Total Operating Income (%) Operating Income (%) 18.6% 4.3% 3.4% 3.4% 3.3% 8.4% 152 3.1% 6.9% 6.2% 5.1% 72 73 47 49 37 33 39 23 26 Q1FY24 Q2 Q3 Q4 Q1FY25 Q1FY24 Q2 Q3 Q4 Q1FY25 o Q1FY
Slide 11: R&D Driving Product Innovation
R&D DRIVING PRODUCT INNOVATION R&D Expense Mix % of Total R&D Spend and Total R&D Spend as % of Total Operating Income ( ) 85 2 76 9% 43% 17% 9.8% Capital Expenses on BE study, R&D Team Post- registrations etc PhDs Size Graduates 7.9% 1% Capital Expenses on Infrastructure & Equipment 6 4 ₹80 Mn Spen
Slide 12: Income Statement
INCOME STATEMENT Particulars (₹ Mn) Q1FY25 Q1FY24 Change % (YoY) FY24 FY23 Change % (YoY) Total Operating Income 818 674 21.4% 3,674 3,985 (7.8%) Other Income 10 11 (9.1%) 52 64 (19.2%) Total Income 828 685 20.9% 3,725 4,049 (8%) EBITDA 90 59 52.5% 465 584 (20.3%) EBITDA % 11% 8.8% 220bps 12.7% 14.7
Slide 13: Shareholding
SHAREHOLDING Ownership % (June 2024) Traded Volume (In K) BSE+NSE 22,129 42% 18,446 15,690 16,005 6,112 5,947 5,322 4,950 5,109 4,641 4,402 4,034 3,365 1,662 14% 343 33% 4% 7% Promoter Other Public Shareholding • Number of Shareholders in Q1FY25 accounted to 17.3K HNI NRI and foreign individuals • T
Slide 14: Share Price Movement
SHARE PRICE MOVEMENT ZIM (BSE) vs BSE S&P Healthcare Index ZIM (NSE) vs Nifty Healthcare Index 12,380 11,837 11,989 35,053 35,328 33,816 11,000 9,487 10,350 31,549 9, 622 9,865 9, 608 28, 194 8, 550 26, 789 27,272 8, 317 8, 009 23, 681 128 22, 182 128 123 123 117 115 115 117 115 115 113 111 113 113
Slide 15: Thank You
THANK YOU INVESTOR RELA TI ONS ZIM’s Investor Relations Mr. Zain Daud zain.daud@zimlab.in M: +91 9022434631 GoIndia Advisors – IR Firm Ms. Sheetal Khanduja Ms. Deepika Sharma Ms. Priya Sen sheetal@goindiaadvisors.com deepika@goindiaadvisors.com priya@goindiaadvisors.com M:+91 9769364166 M:+91 845102